Amancy, France

Philippe Favreau

USPTO Granted Patents = 1 



Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Philippe Favreau: Innovator in Local Anesthetics

Introduction: Philippe Favreau is an esteemed inventor based in Amancy, France. With a focus on the medical field, his work has led to significant advancements in the area of pain management. He is most recognized for his innovative contributions as a researcher at the Centre National de la Recherche Scientifique.

Latest Patents: Favreau holds a patent titled "Mu-conotoxin peptides and use thereof as a local anesthetic." This invention introduces novel mu-conotoxin peptides, along with biologically active fragments and variants. The patented technology outlines their potential applications in pharmaceutical compositions for the treatment or prevention of pain, particularly in the preparation of anesthetics.

Career Highlights: As a dedicated researcher, Philippe Favreau has made remarkable strides in his field. His patent showcases not only his creative prowess as an inventor but also his commitment to improving patient care through innovative medical solutions.

Collaborations: Throughout his career, Favreau has collaborated with notable colleagues such as Evelyne Benoit and Jordi Molgo. These collaborations have played a crucial role in advancing his research and the development of his patented technologies, highlighting the importance of teamwork in scientific innovation.

Conclusion: Philippe Favreau is a significant figure in the realm of local anesthetics, and his patent on mu-conotoxin peptides marks a noteworthy contribution to pain management treatments. His ongoing work at the Centre National de la Recherche Scientifique continues to pave the way for future innovations in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…